<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39370186</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0019-5707</ISSN><JournalIssue CitedMedium="Internet"><Volume>71 Suppl 2</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>The Indian journal of tuberculosis</Title><ISOAbbreviation>Indian J Tuberc</ISOAbbreviation></Journal><ArticleTitle>Comparison of treatment adherence among TB patients with and without COVID-19 in South India.</ArticleTitle><Pagination><StartPage>S214</StartPage><EndPage>S220</EndPage><MedlinePgn>S214-S220</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijtb.2024.05.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0019-5707(24)00076-3</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The present study aimed to compare the adherence to anti-TB treatment among post-COVID-19 pulmonary TB cases and TB patients without a history of COVID-19 in South India.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, cross sectional study was conducted in all drug-sensitive pulmonary tuberculosis patients in National TB Elimination Program. The research investigates the impact of the COVID-19 pandemic on TB management, considering both subjective and objective measures of adherence. Data were collected using a validated instrument for subjective assessment and urine metabolite testing for objective evaluation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results reveal significant differences (p &lt; 0.05) between subjective and objective adherence measures, emphasizing the need for accurate and comprehensive assessment methods. However, there is no statistically significant difference (p &gt; 0.05) in adherence to anti-TB treatment among post-COVID-19 pulmonary TB cases and TB patients without a history of COVID-19 in South India. The reason for non-adherence in both groups were ATT side effects, loss of daily wages, forgetting to take medication and lazy to take medications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study concluded that there is no statistically significant difference (p &gt; 0.05) in adherence to anti-TB treatment among post-COVID-19 pulmonary TB cases and TB patients without a history of COVID-19.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thamineni</LastName><ForeName>Rajavardhana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Balaji College of Pharmacy, Ananthapuramu, 515 002, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradeepkumar</LastName><ForeName>Bhupalam</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research, Ananthapuramu, 515 002, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padmapriya J</LastName><ForeName>Chandana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Balaji College of Pharmacy, Ananthapuramu, 515 002, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajanandh</LastName><ForeName>Mg</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Deemed to Be University, Kattankulathur, Chennai, 603 203, Tamil Nadu, India. Electronic address: mgr@srmist.edu.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Tuberc</MedlineTA><NlmUniqueID>0373027</NlmUniqueID><ISSNLinking>0019-5707</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014397" MajorTopicYN="Y">Tuberculosis, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="Y">Medication Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="Y">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Daily dose regimen</Keyword><Keyword MajorTopicYN="N">Medication adherence</Keyword><Keyword MajorTopicYN="N">Objective adherence</Keyword><Keyword MajorTopicYN="N">Subjective adherence</Keyword><Keyword MajorTopicYN="N">Tuberculosis</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>20</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39370186</ArticleId><ArticleId IdType="doi">10.1016/j.ijtb.2024.05.001</ArticleId><ArticleId IdType="pii">S0019-5707(24)00076-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>